Search

Search Constraints

You searched for: Author/Creator Cartabellotta, F.

Search Results

2. Current epidemiology of HCV in Sicily: the RESIST-HCV model. (October 2019)

3. Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. (February 2019)

4. Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort. Issue 1 (February 2018)

5. Early occurrence of hepatocellular carcinoma (HCC) in patients with HCV cirrhosis treated with direct-acting antivirals (DAAs). Issue 1 (16th February 2017)

6. Efficacy of oral direct acting antivirals for treatment of advanced chronic hepatitis or compensated cirrhosis due to hepatitis C virus infection: The real-life experience of the Sicily registry. Issue 1 (16th February 2017)

7. Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct‐acting antivirals? A prospective multicentre study. Issue 7 (9th August 2017)

8. Non-invasive tools to ruling out large varices: RESIST-HCV vs Baveno VI criteria in a large cohort of patients with HCV cirrhosis. Issue 1 (16th February 2017)

9. OC.07.1 DIRECT ACTING ANTIVIRALS AFTER SUCCESSFUL TREATMENT OF EARLY HEPATOCELLULAR CARCINOMA IMPROVE SURVIVAL AND REDUCE HEPATIC DECOMPENSATION IN HCV-CIRRHOTIC PATIENTS. (25th March 2019)

10. PC.01.10 LIVER AND CARDIOVASCULAR MORTALITY AFTER DAAS: DATA FROM THE RESIST-HCV COHORT. (25th March 2019)